Las cepas del bacilo tuberculoso con farmacorresistencia (TB-DR) son más difíciles de tratar que las
farmacosensibles y amenazan el progreso mundial hacia los objetivos establecidos por la Estrategia Fin de
la TB, de la Organización Mundial de la Salud (OMS). Por lo tanto, existe una necesidad imperio...
Isoniazid (H) is one of the most important first-line medicines for the treatment of active
tuberculosis (TB) and latent TB infection (LTBI), with high bactericidal activity and a good safety profile. The emergence of TB strains resistant to isoniazid threaten to reduce the effectiveness of TB treatment....
Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...
Molecular Probe Techniques,
Rifamycins/therapeutic use,
Isoniazid/therapeutic use,
Tuberculosis, Multidrug-Resistant/diagnosis,
Antitubercular Agents/therapeutic use,
Isoniazid/pharmacology,
Rifampin/pharmacology,
Mycobacterium tuberculosis/drug effects,
Drug Resistance, Bacterial,
Reproducibility of Results
